Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Vincristine 5Methotrexate 5Dexamethasone 5Cytarabine 5Cyclophosphamide 5Inotuzumab Ozogamicin 4blinatumomab 3Rituximab 3Prednisone 3Doxorubicin 3venetoclax 2prednylidene 2pegaspargase 2merphos 2deltacortene 2Mercaptopurine 2Asparaginase 2olverembatinib 1ofatumumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1azathiopurine 1auricularum 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Spinal Puncture 1Specimen Handling 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡